Navin Fluorine International LtdQ2 FY24
Navin Fluorine International Ltd Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹7,303P/E: 53.7Market Cap: ₹35.9K CrSector: Chemicals & Petrochemicals
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- →FY25 expected to see recovery in agrochemical demand in the second half after inventory rationalization.
- →Rs. 540 crore agro-specialty CAPEX plant to commence commercial production by September FY25, targeting full capacity utilization and meeting firm purchase orders.
- →FY25 revenues expected to improve with increased capacity utilization and ramp-up of new projects.
- →FY26 anticipated to see better performance than FY25, driven by new capacities coming online.
- →FY27 expected to hit Rs. 100 crore aspirations for CDMO business, with significant capacity expansion completing end of calendar year 2025.
- →R32 capacity expansion (additional 4,500 tonnes) on track to complete by February 2025 to meet strong market demand.
- →Specialty chemical pipeline growing with new molecules expected to contribute incremental Rs. 60-80 crore revenue by 2027.
- →Overall revenue growth guided by ramp-up of CAPEX projects and improving market conditions, particularly in second half of FY25 onward.
Margin guidance
Category 3- →FY25 expected to witness gradual recovery in agrochemicals with demand uptick in second half, aiding revenue growth.
- →CDMO segment to see improvement with increasing late-stage commercial molecules; FY25 better than FY24 anticipated.
- →FY25 operating EBITDA margin improved sequentially (Q1 at 19.2%), with marginal margin expansion planned through the year.
- →Rs. 540 crore agrochemical plant to commission in September FY25, expected to contribute peak revenues by FY27.
- →Capacity expansions (R32, HF, cGMP-4) expected to drive medium-term revenue growth.
- →FY27 target of Rs. 100 crore revenue in CDMO segment based on new capacity coming online late calendar 2025.
- →Continuous cost optimization and R&D investments to protect and improve EBIT and ROCE.
- →Earnings impacted in short term by higher depreciation and interest costs linked to new CAPEX.
- →Overall, improving margins and rising capacity utilization expected to support earnings and EPS growth post FY25.
3 more insights locked — sign up free to unlock
Fundraise plans
- →There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript.
- →The company is focused on maintaining a strong balance sheet, with a net debt to equity ratio of 0.38x as of June 2024, reflecting financial strength.
- →Interest costs have decreased quarter-on-quarter due to efforts like reducing working capital borrowings and negotiating better spread rates with lenders.
- →Ongoing CAPEX projects (Rs. 540 crore agro-specialty plant, Rs. 450 crore AHF project, Rs. 288 crore cGMP-4, Rs. 84 crore R32 capacity expansion, and Rs. 30 crore new capability in Surat) are advancing as planned, with no mention of raising additional funds for these.
- →The company emphasizes internal financial discipline and improving cash flow without indicating the need for external fundraising at this time.
Order book
Yes- →The Rs. 540 crore agrochemical plant, commissioning in September FY25, has firm, non-cancellable orders from a global major.
- →This order book is part of a mature relationship involving multiple products (4-5) under supply agreements.
- →For FY25, the plant's capacity utilization is expected to be dedicated 50%, fulfilling existing firm orders.
- →Additional campaigns (~100 metric tonnes) will be run to qualify products for future orders.
- →The CDMO business has a strong pipeline; confident that FY25 will be better than FY24.
- →FY27 is targeted to reach the aspiration of $100 million revenue in CDMO, backed by capacity expansion coming online end of calendar year 2025 (FY26).
- →Orderbook visibility in CDMO is improving quarter-on-quarter.
- →Domestic CDMO supplies happen temporarily until product registrations with global majors are complete; then exports commence directly.
- →Overall, orderbook is robust, backed by long-term supply contracts and ongoing strong customer relationships.
Capex plans
Yes- →Rs. 540 crore agro-specialty project targeted for commercial production by September FY25; firm purchase orders secured for FY25.
- →Rs. 450 crore AHF project to enhance HF capacity by 40,000 MT at Dahej, on track to commence by end FY25/early FY26.
- →Rs. 288 crore cGMP-4 CAPEX underway, planned commissioning by end of calendar year 2025.
- →Additional R32 CAPEX of Rs. 84 crores to boost capacity by 4,500 tonnes, expected completion by February 2025.
- →Rs. 30 crore CAPEX for new capability development in Surat, progressing for commissioning in Q2 FY25.
- →Plans to upscale capacity to aspirational Rs. 100 million in CDMO by FY27, with extra capacity coming on stream late calendar year 2025.
- →Ongoing upgrades to flexibility at the agro plant to cater to more molecules at customer's cost.
How does Navin Fluorine International Ltd rank vs peers in Chemicals & Petrochemicals?
Pro feature1Navin Fluorine International Ltd
Rev 3Mar 3
See full Chemicals & Petrochemicals sector rankings
Want more stocks like Navin Fluorine International Ltd?
Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.
Build my portfolio